Quick Answer
Korro Bio, Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2022.
Korro Bio, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2022 | $0.00 | -100.0% |
| 2021 | $14.07M | -62.0% |
| 2020 | $36.98M | +27.8% |
| 2019 | $28.95M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2022 | $0.00 | — | — |
| June 30, 2022 | $0.00 | -100.0% | — |
| March 31, 2022 | $0.00 | -100.0% | — |
| September 30, 2021 | $0.00 | -100.0% | -100.0% |
| June 30, 2021 | $9.42M | +10.5% | +102.5% |
| March 31, 2021 | $4.65M | -36.0% | -58.6% |
| September 30, 2020 | $11.25M | -53.6% | +32.0% |
| June 30, 2020 | $8.52M | — | +17.3% |
- Korro Bio, Inc. showed a decrease of -100.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2019–2022 period, Korro Bio, Inc.’s revenue (asc 606) has declined by 100.0% (from $28.95 million to $0.00).
- The most recent figure is from Korro Bio, Inc.’s fiscal year 2022 report (Form 10-K), filed with the SEC on March 10, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: